Study finds apparent benefits of addition of adjunctive antidepressants
to mood stabilizers, Tel Aviv University researchers say
Tel Aviv — Bipolar disorder patients, who comprise 1-4 percent of the population, suffer from chronic mood swings that alternate between “manic” episodes, characterized by inflated energy, self-esteem and risky behavior, and depression, which can take a suicidal turn.
A new Tel Aviv University study finds that antidepressant therapy minimizes the incidence of rehospitalization from bipolar depression.
“This study provides hope for bipolar disorder patients by supporting the efficacy and safety of antidepressant therapy use for bipolar depression, which has always been considered a ‘treatment-resistant’ disabling state,” says Dr. Eldar Hochman of TAU’s Sackler Faculty of Medicine and Geha Mental Health Center, who led the research for the study. It was published in European Neuropsychopharmacology.
“Our study suggests that adding antidepressant therapy to mood stabilizers or atypical antipsychotics after hospitalization for bipolar depression can prevent rehospitalization in the short- and long-term. Adding the antidepressant therapy doesn’t increase the risk of manic episodes,” Dr. Hochman says.
“Our results are immediately relevant to clinical practice and should encourage clinicians to prescribe antidepressant therapy to bipolar disorder depression in patients with adequate mood stabilization.”
New scientific evidence to support therapy
Antidepressants are widely used to manage bipolar depression, but there has been little evidence to support their effectiveness until now. “Our study supports a positive risk-benefit ratio for the use of antidepressants in treating the depression of ‘real-world’ bipolar disorder patients,” says Dr. Hochman.
In the study, 98 patients with bipolar disorder were retrospectively observed for six-month and one-year rehospitalization rates. They had been hospitalized with a depressive episode between 2005 and 2013 at Geha Mental Health Center in Israel.
“We used a retrospective chart review to compare six-month and one-year rehospitalization rates of bipolar disorder patients hospitalized with a depressive episode. They were treated at discharge with mood stabilizers and/or atypical antipsychotics with or without antidepressants,” says Dr. Hochman. “We wanted to track their treatment at discharge — with or without antidepressants — and used multivariable survival models adjusted for variations known to influence rehospitalization.”
The research found that, within one year following discharge, 81.7% of the patients who were treated with antidepressants in addition to mood stabilizers avoided rehospitalization, versus 57.6% of the patients who did not undergo the same combination.
Avoiding antidepressant treatment alone
“Antidepressant treatment pursued alone, without an additional mood stabilizing therapy, should be avoided in bipolar depression due to an increased risk for manic episodes,” Dr. Hochman says.
The researchers are currently studying the socio-demographic and clinical prognostic factors affecting bipolar disorder course outcomes. “We hope that our data will help to develop a disease staging system that will allow individuals to reclaim control of their lives,” Dr. Hochman concludes.
Dr. Yahav Shvartzman authored the study together with Dr. Hochman, and Dr. Amir Krivoy, Dr. Avi Valevski, Dr. Shay Gur and Dr. Abraham Weizman, all of TAU’s Sackler Faculty of Medicine and Geha Mental Health Center, contributed to the research.
American Friends of Tel Aviv University (AFTAU) supports Israel’s most influential, comprehensive and sought-after center of higher learning, Tel Aviv University (TAU). TAU is recognized and celebrated internationally for creating an innovative, entrepreneurial culture on campus that generates inventions, startups and economic development in Israel. For three years in a row, TAU ranked 9th in the world, and first in Israel, for alumni going on to become successful entrepreneurs backed by significant venture capital, a ranking that surpassed several Ivy League universities. To date, 2,400 patents have been filed out of the University, making TAU 29th in the world for patents among academic institutions.